$OPK
OPKO HEALTH, INC. Stock $opk

$opk Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000143774924033931 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$173.6M	$178.6M
YoY Change		-2.78%	-0.64%
Cost Of Revenue		$133.5M	$130.9M
YoY Change		1.99%	-11.82%
Gross Profit		$40.13M	$47.70M
YoY Change		-15.87%	52.4%
Gross Profit Margin		23.11%	26.71%
Selling, General & Admin		$98.20M	$72.24M
YoY Change		35.94%	-9.33%
% of Gross Profit		244.72%	151.45%
Research & Development		$28.77M	$19.44M
YoY Change		48.03%	3.42%
% of Gross Profit		71.69%	40.74%
Depreciation & Amortization		$24.16M	$26.18M
YoY Change		-7.71%	-6.47%
% of Gross Profit		60.21%	54.89%
Operating Expenses		$159.4M	$243.0M
YoY Change		-34.4%	-9.18%
Operating Profit		$14.22M	-$64.41M
YoY Change		-122.07%	-26.66%
Interest Expense		-$14.43M	$3.384M
YoY Change		-526.48%	-277.73%
% of Operating Profit		-101.52%
Other Income/Expense, Net		$34.20M	-$13.97M
YoY Change		-344.82%	-63.76%
Pretax Income		$48.42M	-$78.38M
YoY Change		-161.78%	-37.98%
Income Tax		$23.53M	$6.075M
% Of Pretax Income		48.59%
Net Earnings		$24.89M	-$84.47M
YoY Change		-129.47%	-1.88%
Net Earnings / Revenue		14.33%	-47.3%
Basic Earnings Per Share		$0.04	-$0.11
Diluted Earnings Per Share		$0.03	-$0.11
COMMON SHARES
Basic Shares Outstanding	682.5M	697.4M	773.1M
Diluted Shares Outstanding		998.4M	751.5M

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$406.4M	$138.6M
YoY Change	193.22%	-23.36%
Cash & Equivalents	$400.1M	$138.6M
Short-Term Investments
Other Short-Term Assets	$9.295M	$7.003M
YoY Change	32.73%	10.46%
Inventory	$59.41M	$68.96M
Prepaid Expenses
Receivables	$106.6M	$117.4M
Other Receivables	$32.08M	$9.100M
Total Short-Term Assets	$629.6M	$357.2M
YoY Change	76.25%	-13.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$135.1M	$78.17M
YoY Change	72.81%	-34.72%
Goodwill	$535.9M	$594.5M
YoY Change	-9.86%	3.65%
Intangibles	$641.4M	$758.4M
YoY Change	-15.43%
Long-Term Investments	$0.00	$19.40M
YoY Change	-100.0%	-75.07%
Other Assets	$18.51M	$9.333M
YoY Change	98.34%	-3.14%
Total Long-Term Assets	$1.626B	$1.699B
YoY Change	-4.29%	-6.15%
TOTAL ASSETS
Total Short-Term Assets	$629.6M	$357.2M
Total Long-Term Assets	$1.626B	$1.699B
Total Assets	$2.256B	$2.057B
YoY Change	9.7%	-7.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$62.72M	$66.80M
YoY Change	-6.11%	34.28%
Accrued Expenses	$122.8M	$92.37M
YoY Change	32.95%	-17.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.509M	$1.772M
YoY Change	-14.84%	-98.16%
Total Short-Term Liabilities	$211.7M	$200.6M
YoY Change	5.54%	-24.96%
LONG-TERM LIABILITIES
Long-Term Debt	$3.529M	$7.927M
YoY Change	-55.48%	-94.89%
Other Long-Term Liabilities	$36.50M	$25.62M
YoY Change	42.5%	13.59%
Total Long-Term Liabilities	$641.0M	$411.6M
YoY Change	55.76%	25.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$211.7M	$200.6M
Total Long-Term Liabilities	$641.0M	$411.6M
Total Liabilities	$852.7M	$612.1M
YoY Change	39.3%	2.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.079B	-$1.945B
YoY Change	6.87%	11.95%
Common Stock	$7.124M	$7.817M
YoY Change	-8.87%	0.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.403B	$1.445B
YoY Change
Total Liabilities & Shareholders Equity	$2.256B	$2.057B
YoY Change	9.7%	-7.56%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	$24.89M	-$84.47M
YoY Change	-129.47%	-1.88%
Depreciation, Depletion And Amortization	$24.16M	$26.18M
YoY Change	-7.71%	-6.47%
Cash From Operating Activities	-$77.08M	$33.10M
YoY Change	-332.87%	-202.68%
INVESTING ACTIVITIES
Capital Expenditures	$7.937M	$4.200M
YoY Change	88.98%	-155.18%
Acquisitions
YoY Change
Other Investing Activities	$255.7M	$700.0K
YoY Change	36431.57%	-76.11%
Cash From Investing Activities	$247.8M	-$3.600M
YoY Change	-6982.89%	-23.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	206.1M	2.100M
YoY Change	9716.19%	-75.13%
NET CHANGE
Cash From Operating Activities	-77.08M	33.10M
Cash From Investing Activities	247.8M	-3.600M
Cash From Financing Activities	206.1M	2.100M
Net Change In Cash	376.8M	31.60M
YoY Change	1092.55%	-210.98%
FREE CASH FLOW
Cash From Operating Activities	-$77.08M	$33.10M
Capital Expenditures	$7.937M	$4.200M
Free Cash Flow	-$85.02M	$28.90M
YoY Change	-394.17%	-217.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	OPKO HEALTH, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0000944809
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1250000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1250000000
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	712283206
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	781936885
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	29800177
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	8655082
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	836400000	usd
	us-gaap	Open Tax Year OpenTaxYear	2015 2016 2017 2018 2019 2020 2021
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33528
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-2402409
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4400 Biscayne Blvd.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33137
	dei	City Area Code CityAreaCode	305
	dei	Local Phone Number LocalPhoneNumber	575-4100
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	OPK
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	682483029
CY2024Q3	opk	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Current CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsCurrent	406400000	usd
CY2023Q4	opk	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Current CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsCurrent	95881000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	106579000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	123379000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	59408000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	65697000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	57249000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24519000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	629636000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	309476000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	72271000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	75429000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	641396000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	740283000	usd
CY2024Q3	opk	Capitalized Research And Development In Process CapitalizedResearchAndDevelopmentInProcess	195000000	usd
CY2023Q4	opk	Capitalized Research And Development In Process CapitalizedResearchAndDevelopmentInProcess	195000000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	535868000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	598260000	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	100609000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	16082000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	62812000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	68088000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18511000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9080000	usd
CY2024Q3	us-gaap	Assets Assets	2256103000	usd
CY2023Q4	us-gaap	Assets Assets	2011698000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	62721000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	69677000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	122806000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	90086000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12741000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12996000	usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	170000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2024Q3	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	13222000	usd
CY2023Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	27293000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	211660000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	200052000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52057000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	54140000	usd
CY2024Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	178695000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	214325000	usd
CY2024Q3	us-gaap	Senior Long Term Notes SeniorLongTermNotes	245358000	usd
CY2023Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	0	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	128412000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	126773000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	36504000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27189000	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	641026000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	422427000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	852686000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	622479000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	7124000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7820000	usd
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1791000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1791000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3516735000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3433006000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-39614000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-38030000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2079037000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2011786000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1403417000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1389219000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2256103000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2011698000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	173632000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	178595000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	529504000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	681591000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	98203000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	72240000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	237191000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	227676000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28770000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19435000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	74789000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70199000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1125000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1023000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	20433000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21534000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	62290000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	64543000	usd
CY2024Q3	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	121493000	usd
CY2023Q3	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-0	usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	121493000	usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-0	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	159416000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	243002000	usd
	us-gaap	Operating Expenses OperatingExpenses	648430000	usd
	us-gaap	Operating Expenses OperatingExpenses	769566000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	14216000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-64407000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-118926000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-87975000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2928000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	970000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4132000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3077000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	17359000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3384000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	33225000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10053000	usd
CY2024Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-1000	usd
CY2023Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	88000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-26161000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-829000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	48636000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11645000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	128834000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16045000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	34204000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13971000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	73580000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23850000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	48420000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-78378000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-45346000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-111825000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23527000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6075000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21898000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10456000	usd
CY2024Q3	opk	Income Loss From Continuing Operations Net Of Tax Before Equity Method Investments And Noncontrolling Interest Total IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal	24893000	usd
CY2023Q3	opk	Income Loss From Continuing Operations Net Of Tax Before Equity Method Investments And Noncontrolling Interest Total IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal	-84453000	usd
	opk	Income Loss From Continuing Operations Net Of Tax Before Equity Method Investments And Noncontrolling Interest Total IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal	-67244000	usd
	opk	Income Loss From Continuing Operations Net Of Tax Before Equity Method Investments And Noncontrolling Interest Total IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal	-122281000	usd
CY2024Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3000	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-20000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-7000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-99000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	24890000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-84473000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-67251000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-122380000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.1
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.1
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	694622466
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	751525007
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	699675944
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	751716692
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	998363636
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	751525007
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	699675944
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	751716692
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	24890000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-84473000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-67251000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-122380000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	7038000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9554000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1585000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3173000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	31928000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-94027000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68836000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-125553000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	1395317000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2784000	usd
CY2024Q3	opk	Adjustments To Additional Paid In Capital Repurchase Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalRepurchaseOfConvertibleDebt	2853000	usd
CY2024Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	23759000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	24890000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	7038000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1403417000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1389219000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7983000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-208000	usd
	opk	Adjustments To Additional Paid In Capital Repurchase Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalRepurchaseOfConvertibleDebt	2853000	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	73759000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-67251000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1584000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1403417000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1535348000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3218000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-84473000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9553000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1444568000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1561648000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8745000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-273000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-122380000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3172000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1444568000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-67251000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-122380000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74137000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	79315000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	12753000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	2057000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1328000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	908000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-7000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-99000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7983000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8746000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	9489000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1444000	usd
	opk	Changes In Fair Value Gain Loss In Equity Securities Fvni And Derivative Instruments ChangesInFairValueGainLossInEquitySecuritiesFvniAndDerivativeInstruments	94626000	usd
	opk	Changes In Fair Value Gain Loss In Equity Securities Fvni And Derivative Instruments ChangesInFairValueGainLossInEquitySecuritiesFvniAndDerivativeInstruments	-14406000	usd
	opk	Gain Loss On Conversion Of Debt GainLossOnConversionOfDebt	-725000	usd
	opk	Gain Loss On Conversion Of Debt GainLossOnConversionOfDebt	-0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1023000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	7695000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	7307000	usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	121493000	usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15680000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8741000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6452000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4082000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8395000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-10220000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-564000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2666000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6527000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	191000	usd
	opk	Increase Decrease In Foreign Currency Measurement IncreaseDecreaseInForeignCurrencyMeasurement	-3575000	usd
	opk	Increase Decrease In Foreign Currency Measurement IncreaseDecreaseInForeignCurrencyMeasurement	24000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	44952000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1374000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-139080000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	10097000	usd
	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	-0	usd
	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	5000000	usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	46731000	usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	364000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1454000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	-0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	169000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1109000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	19597000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	13253000	usd
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	210378000	usd
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	236227000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16780000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	230000000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	250000000	usd
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	13385000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	73759000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	-0	usd
	opk	Proceeds From Repurchase Of Stock Options And Warrants Exercised ProceedsFromRepurchaseOfStockOptionsAndWarrantsExercised	-208000	usd
	opk	Proceeds From Repurchase Of Stock Options And Warrants Exercised ProceedsFromRepurchaseOfStockOptionsAndWarrantsExercised	-273000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	4881000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-0	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	448459000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	515318000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	465301000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	519597000	usd
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	146287000	usd
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	3000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	224638000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7552000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2399000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-335000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	324184000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14570000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	95881000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153191000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	420065000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	138621000	usd
	us-gaap	Interest Paid Net InterestPaidNet	12982000	usd
	us-gaap	Interest Paid Net InterestPaidNet	10748000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3801000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-823000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	713000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5966000	usd
	opk	Common Stock Options And Warrants Net Exercised CommonStockOptionsAndWarrantsNetExercised	208000	usd
	opk	Common Stock Options And Warrants Net Exercised CommonStockOptionsAndWarrantsNetExercised	301000	usd
	opk	Shares Included In Business Divesture Cash Flow Impact SharesIncludedInBusinessDivestureCashFlowImpact	0	usd
	opk	Shares Included In Business Divesture Cash Flow Impact SharesIncludedInBusinessDivestureCashFlowImpact	6689000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	36200000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	34600000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Use of estimates</i>. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"></p>
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400079000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95881000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6321000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	13665000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	420065000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95881000	usd
CY2024Q3	us-gaap	Inventory Write Down InventoryWriteDown	600000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1600000	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	2600000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	4000000	usd
CY2024Q3	opk	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill And Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets	1400000000	usd
CY2023Q4	opk	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill And Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets	1500000000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	535900000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	598300000	usd
CY2024Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	836400000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	20400000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	62300000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21500000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	64500000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	3700000	usd
	us-gaap	Depreciation Depreciation	11900000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	4800000	usd
	us-gaap	Depreciation Depreciation	14800000	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	9900000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Concentration of credit risk and allowance for credit losses</i>. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">While we have receivables due from federal and state governmental agencies, such receivables are <em style="font: inherit;">not</em> a credit risk because federal and state governments fund the related healthcare programs. Payment is primarily dependent upon submitting appropriate documentation. On <em style="font: inherit;"> September 30, 2024</em> and <em style="font: inherit;"> December 31, 2023</em>, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 6.5% and 6.7%, respectively, of our consolidated Accounts receivable, net. The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At <em style="font: inherit;"> September 30, 2024</em> and <em style="font: inherit;"> December 31, 2023</em>, receivables due from patients represented approximately 2.2% and 2.0%, respectively, of our consolidated Accounts receivable, net.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that <em style="font: inherit;"> may </em>affect a customer’s ability to pay. Actual results could differ from those estimates. The allowance for credit losses was $2.0 million on each of <em style="font: inherit;"> September 30, 2024</em> and <em style="font: inherit;"> December 31, 2023</em>. The credit loss expense for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2024</em>, was a reversal expense of $75.2 thousand and $67.5 thousand of expense, respectively. The credit loss expense for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023</em>, was $98.3 thousand and $183.4 thousand, respectively.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">As of <em style="font: inherit;"> September 30, 2024</em>, accounts receivable included $1.6 million of revenue earned under the BARDA Contract (as defined in Note <em style="font: inherit;">14</em>). As of <em style="font: inherit;"> December 31, 2023, </em>accounts receivable included $0.6 million under this contract. Refer to Note <em style="font: inherit;">13,</em> Government Contract Revenue for further information on government contracts and to Note <em style="font: inherit;">14,</em> Strategic Alliances for further information on the BARDA Contract.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"></p>
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000000	usd
CY2024Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-75200000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	67500000	usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	98300000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	183400000	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2800000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8000000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	3200000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8700000	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4100000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	100000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3800000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1900000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	24890000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-84473000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67251000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-122380000	usd
CY2024Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	32000	usd
CY2023Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	31781000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-84473000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-67251000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-122380000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	694622466
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	751525007
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	699675944
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	751716692
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	76922
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0
CY2024Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	303741170
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	998363636
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	751525007
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	699675944
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	751716692
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.1
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.1
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	83074689
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	286281585
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	82368398
CY2024Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2024Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	0
CY2024Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	549687
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	384378
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18750
CY2023Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	0
CY2023Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	18750
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18750
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	549680
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	405721
CY2024Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	108583000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	125379000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2004000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	106579000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	123379000	usd
CY2024Q3	us-gaap	Other Inventory Supplies OtherInventorySupplies	16218000	usd
CY2023Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	25864000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	34206000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	35582000	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2265000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1731000	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	10491000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8981000	usd
CY2024Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3772000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	6461000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	59408000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	65697000	usd
CY2024Q3	us-gaap	Escrow Deposit EscrowDeposit	23750000	usd
CY2023Q4	us-gaap	Escrow Deposit EscrowDeposit	0	usd
CY2024Q3	us-gaap	Prepaid Taxes PrepaidTaxes	6767000	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	4211000	usd
CY2024Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	9572000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	6177000	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	6302000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3848000	usd
CY2024Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1563000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2610000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	9295000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7673000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	57249000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24519000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	517400000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	488694000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	641396000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	740283000	usd
CY2024Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	38474000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	28952000	usd
CY2024Q3	opk	Accrued Clinical Trials AccruedClinicalTrials	3725000	usd
CY2023Q4	opk	Accrued Clinical Trials AccruedClinicalTrials	7624000	usd
CY2024Q3	opk	Accrued Commitments And Contingencies Current AccruedCommitmentsAndContingenciesCurrent	11141000	usd
CY2023Q4	opk	Accrued Commitments And Contingencies Current AccruedCommitmentsAndContingenciesCurrent	8088000	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	6021000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2601000	usd
CY2024Q3	opk	Accrued Gross To Net Provision AccruedGrossToNetProvision	6033000	usd
CY2023Q4	opk	Accrued Gross To Net Provision AccruedGrossToNetProvision	9420000	usd
CY2024Q3	opk	Accrued Inventory Not Yet Billed AccruedInventoryNotYetBilled	2306000	usd
CY2023Q4	opk	Accrued Inventory Not Yet Billed AccruedInventoryNotYetBilled	1653000	usd
CY2024Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1855000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2827000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4375000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3470000	usd
CY2024Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	15334000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1384000	usd
CY2024Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	767000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1544000	usd
CY2024Q3	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1521000	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1822000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	31254000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20701000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	122806000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	90086000	usd
CY2024Q3	us-gaap	Postemployment Benefits Liability Noncurrent PostemploymentBenefitsLiabilityNoncurrent	16284000	usd
CY2023Q4	us-gaap	Postemployment Benefits Liability Noncurrent PostemploymentBenefitsLiabilityNoncurrent	0	usd
CY2024Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	3529000	usd
CY2023Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	7709000	usd
CY2024Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4689000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7274000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7000	usd
CY2024Q3	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	11995000	usd
CY2023Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	12199000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	36504000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27189000	usd
CY2023Q4	us-gaap	Goodwill Gross GoodwillGross	636283000	usd
CY2024Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	38023000	usd
	opk	Goodwill Acquired Disposed Of During Period GoodwillAcquiredDisposedOfDuringPeriod	-63318000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	926000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	535868000	usd
CY2024Q3	us-gaap	Equity Method Investments EquityMethodInvestments	-0	usd
CY2024Q3	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	1782000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	-0	usd
CY2023Q4	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	2942000	usd
CY2024Q3	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	790000	usd
CY2024Q3	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	0	usd
CY2023Q4	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	796000	usd
CY2023Q4	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	420000	usd
CY2024Q3	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	92166000	usd
CY2023Q4	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	9786000	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	130000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	116000	usd
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	7521000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5382000	usd
CY2024Q3	opk	Equity Investments Carrying Value Of Equity Intruments EquityInvestmentsCarryingValueOfEquityIntruments	2000	usd
CY2023Q4	opk	Equity Investments Carrying Value Of Equity Intruments EquityInvestmentsCarryingValueOfEquityIntruments	2000	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	100609000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	16082000	usd
CY2024Q3	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	600000	usd
CY2023Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	700000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	43000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-411000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-30000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	13000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-411000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	1509000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1993000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3529000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7727000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	440974000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	249345000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	440974000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	249345000	usd
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	50000000	usd
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	0.9067
CY2024Q3	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd		pure
CY2024Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	30013000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	11713000	usd
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	25300000	usd
CY2024Q3	us-gaap	Purchase Obligation PurchaseObligation	44000000	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	2200000	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	19800000	usd
CY2024Q3	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	4900000	usd
CY2023Q4	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	3100000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	14216000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-64407000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-118926000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-87975000	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24163000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26183000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74137000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	79315000	usd
CY2024Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-3000	usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-20000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-7000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-99000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	173632000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	178595000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	529504000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	681591000	usd
CY2024Q3	us-gaap	Assets Assets	2256103000	usd
CY2023Q4	us-gaap	Assets Assets	2011698000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	535868000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	598260000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	62812000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	68088000	usd
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	6544000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	10101000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12741000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12996000	usd
CY2024Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1855000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2827000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52057000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	54140000	usd
CY2024Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4689000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7274000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y1M6D
CY2024Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P7Y1M6D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P6Y2M12D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054	pure
CY2024Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.037	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.038	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3043000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	673000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	11772000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1813000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10937000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	1334000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10775000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	806000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10785000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	203000	usd
CY2024Q3	opk	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	26534000	usd
CY2024Q3	opk	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	1959000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	73846000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	6788000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9048000	usd
CY2024Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	244000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	64798000	usd
CY2024Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	6544000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	15200000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2500000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1500000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	12000000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2200000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	900000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	15101000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	11704000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	354000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	327000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2118000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1919000	usd
	opk	Payments For Leases PaymentsForLeases	17573000	usd
	opk	Payments For Leases PaymentsForLeases	13950000	usd

Files In Submission

Name	View Source	Status
0001437749-24-033931-index-headers.html	Edgar Link	pending
0001437749-24-033931-index.html	Edgar Link	pending
0001437749-24-033931.txt	Edgar Link	pending
0001437749-24-033931-xbrl.zip	Edgar Link	pending
ex_716426.htm	Edgar Link	pending
ex_716427.htm	Edgar Link	pending
ex_716428.htm	Edgar Link	pending
ex_716429.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opk-20240930.xsd	Edgar Link	pending
opk20240930_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
opk-20240930_cal.xml	Edgar Link	unprocessable
opk-20240930_def.xml	Edgar Link	unprocessable
opk-20240930_lab.xml	Edgar Link	unprocessable
opk-20240930_pre.xml	Edgar Link	unprocessable
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
opk20240930_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPK
OPKO HEALTH, INC. Stock $opk

2024 Q4 Form 10-Q Financial Statement

#000143774924033931 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK OPKO HEALTH, INC. Stock $opk

2024 Q4 Form 10-Q Financial Statement

#000143774924033931 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK
OPKO HEALTH, INC. Stock $opk